Loss of apoptotic Bax due to microsatellite mutation contributes to tumor development and chemoresistance. Recently a Bax microsatellite mutation was uncovered in combination with a specific alternative splicing event that could generate a unique Bax isoform (Bax∆2) in otherwise Bax-negative cells. Like the prototype Baxα, Bax∆2 is a potent pro-apoptotic molecule.
Introduction
A microsatellite is a short stretch of repeating DNA sequence that is prone to deletion or insertion due to the slippage of DNA polymerase (1) (2) (3) . Dysfunction of the DNA mismatch repair (MMR) system often results in microsatellite instability (MSI) (4, 5) . The classic example of MSI is Lynch syndrome (6) , in which patients have a high risk of developing many types of cancer, especially hereditary nonpolyposis colorectal cancer (HNPCC) (7, 8) . Over 90% of Lynch syndrome patients have a high level of microsatellite instability (MSI-H) (9) (10) (11) . If a microsatellite sequence is in the DNA coding region, frameshift mutations can disrupt the translational reading frame and cause truncation or premature termination. Many genes with microsatellite frameshift mutations are cancer related, such as Bax, TGF-II, IGFRII, and TCF-4, which are closely associated with MSI-H colon cancer (12) (13) (14) (15) (16) . Loss of these key components significantly contributes to tumor development and chemoresistance (17) (18) (19) .
Bax is a pro-apoptotic Bcl-2 family member (20) (21) (22) . Typically, Bax promotes apoptosis through the activation of the mitochondrial death pathway (23, 24) . Under a non-stimulated condition, Bax localizes in the cytosol as monomers. Upon stimulation by a death signal, Bax translocates to the mitochondrial membrane where it disrupts the mitochondrial membrane, causes the release of cytochrome C, and sequentially activates caspase-9 and caspase-3 for cell death (24, 25) . Bax has several isoforms, mostly generated by alternative splicing between exon 1 and exon 3 or between exon 5 and exon 6 from the prototype Bax pre-mRNA (21, (26) (27) (28) (29) (30) .
These isoforms either universally exist in normal and cancer cells or are only detectable in certain tissues (29) . The pro-apoptotic activity of Bax isoforms can be well preserved as long as the Bax functional BH domains remain intact (31, 32) . Some of the Bax isoforms, such as Baxβ, change the stability of proteins, while others change their potencies of cell death (30, 33) .
Nevertheless, most Bax isoforms promote apoptosis using the same mechanism as the prototype Bax, i.e., through the activation of the mitochondrial death pathway (23, 30, 33, 34 Bax is one of the genes that are frequently mutated in MSI tumors (16, 35) . The inactivation of Bax by a frameshift mutation is found in 50% of HNPCC (16) . The deletion of a single guanine nucleotide (G) in the Bax exon 3 microsatellite tract (from G8 to G7) results in a reading frameshift and "Bax-negative" phenotype due to a premature termination codon. The loss of Bax often promotes tumor growth and increases resistance to chemotherapeutics (17) (18) (19) . Recently, we found that the mutation-mediated loss of Bax could be restored by unique alternative splicing that produces a novel Bax isoform, Bax∆2, which exists only in cells harboring the Bax microsatellite G7 mutation (36, 37) . Bax∆2 transcripts can be detected in both MSI cancer cell lines and primary tumors (36) . Bax∆2 is a more potent apoptotic inducer than Bax (36) . In this study, we show that Bax∆2 proteins determine the chemosensitivity of colon cancer cells. Unlike
Baxthe pro-apoptotic activity of Bax∆2 is mediated by the activation of the caspase-8 pathway rather than the mitochondrial death pathway. Our results uncover a distinct mechanism by which Bax2 induces apoptosis and suggest that Bax∆2 is a potential target for cancer therapy.
Materials and Methods

Materials
Antibody against Bax (N20, against the Bax N-terminus) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The Bax∆2 monoclonal antibody was generated as described (36) . Antibodies against cleaved human specific caspase-8 and mouse specific caspase-8, and 
Transient transfection and RNA interference
Cells were allowed grown in 6-well plates to 70-80% confluences before transfection. Caspase-9 dominant negative construct (LZRS-caspase-9, D/N) (38) and Bid siRNA (5'GGGCAAAAGC UUACAAAUAUU3'), as well as controls, were transfected using lipofectamine 2000 according to the manufacturer's instruction (Life Technology).
Co-immunoprecipitation and immunostaining
Cell pellets were lysed in NP-40 buffer (145 mM NaCl, 5 mM MgCl, 1 mM EGTA, 0. 
Colony formation and invasive assays
A standard colony formation assay was performed as described (39) . Briefly, total 1.5×10 4 cells were seeded in each well in a 6-well plate. After culturing for 3-4 weeks, the colonies were visualized by staining with crystal violet and triplicate samples were counted under the dissecting microscope. The transwell invasion assay was performed by using transwell inserts with 8.0 μm pore size in 6-well plates. Total 5 × 10 5 cells were seeded into the upper chamber and cultured for 24 h. Cells were fixed in the following day with 5% Glutaraldehyde and stained by Toluidine Blue. The inner surface of the upper chamber was carefully wiped using a cotton swab. Invasive cells were counted in three randomly selected fields for each well under a microscope.
Results
The expression of Bax∆2 proteins can be detected in colon cancer cells harboring the Bax microsatellite G7 mutation allele
Bax∆2 is a functional Bax isoform produced by a unique combination of a microsatellite mononucleotide deletion (G8 to G7) in Bax exon 3 and alternative splicing of Bax exon 2 (36). HCT116 colon cancer cells contain mixed populations with different Bax microsatellite statuses as follows: the majority of these cells (94%) have mixed Bax alleles (G8/G7); 4% of these cells have pure Bax G7/G7; and 2% of these cells have pure Bax G8/G8 (17) . It has been shown that further deletion of the Bax G8 allele in the Bax G8/G7 cells results in a Bax null phenotype and leads to partial chemoresistance (17) . We speculated that the population of HCT116 cells harboring the Bax G7 mutation is capable of producing Bax∆2, thus remaining sensitive to chemotherapeutic treatment. To test this scenario, we isolated single-cell populations using a standard 96-well plating method (Fig. 1A) (17) . More than 54 isogenic sub-clones were isolated and genotyped. The following 20 sub-clones were further analyzed by both genomic sequence and splicing analyses: 14 clones contained Bax G8/G7; 6 clones contained G7/G7; and none of the clones contained G8/G8 (Table 1) . Interestingly, all 6 Bax G7/G7 clones contained both detectable transcript products from constitutive splicing and alternative splicing, as determined by RT-PCR (Table 1) . In contrast, all Bax G8/G7 clones contained only constitutive splicing transcripts, and none of these clones contained a detectable product from alternative splicing (Table 1) . These results suggest that not all alleles containing Bax microsatellite mutations are capable of alternative splicing.
To study the ability of the isogenic cells to generate Bax2 transcripts, we further analyzed HCT116 sublines, namely clone #10 (Bax G7/G7) and clone #28 (Bax G8/G7). RT-PCR analysis with primers in Bax exons 1 and 3 revealed that clone #10 (Bax G7/G7) contained both constitutive splicing (upper band) and alternative splicing (lower band), although the constitutive splicing product was predominant (Fig. 1B) . In contrast, clone #28 (Bax G8/G7) only contained constitutive splicing products, albeit the Bax G7 mutated allele. Furthermore, only less than 20% of the total pre-mRNA from the Bax G7/G7 population went through the exon 2 alternative (Fig. 1B) . To further confirm that the alternative splicing product (lower band) was a Bax∆2 transcript, the lower band was excised and subjected to sequence analysis. In addition, the Bax∆2 specific 5' primer covering the junction of exons 1 and 3 was used in the PCR analysis.
As expected, the Bax2 transcript was only detected in clone #10 and the Bax∆2 positive control, but it was not detected in clone #28 and the Baxα negative control (Fig. 1B) . Thus, Bax∆2 transcripts can be easily detected in cells containing the Bax G7/G7 allele.
We then determined the expression of endogenous Bax∆2 proteins in the HCT116 clones #10 and #28 subline cells using a specific anti-Bax2 antibody (36) . Immunoblotting analysis revealed that the endogenous Bax∆2 protein levels were extremely low in clone #10 and undetectable in clone #28 (Fig. 1C) . However, Bax∆2 proteins were easily detected in clone #10 when the cells were treated with MG-132, a proteasomal inhibitor (Fig. 1C) . Under the same conditions, clone #28 had no detectable Bax∆2 proteins. This result was consistent with previous observations (Fig. 1B) that Bax G8/G7 cannot generate detectable Bax∆2 transcript and protein.
Of note, both clone #10 and clone #28 had no detectable parental Baxα proteins, as analyzed by immunoblotting using several anti-Baxα antibodies (Fig. 1C and data not shown) . Taken together, these results indicate that cancer cells harboring Bax G7/G7 mutations are capable of generating Bax∆2 proteins, although the Bax2 proteins appear to be unstable and prone to proteasomal degradation.
To analyze the physiological characteristics of these two HCT116 isogenic sublines, the growth rate, invasion ability and colony formation of both clones #10 and #28 cells were analyzed. We found that clones #10 and #28 were quite similar to each other in terms of growth rate (Fig. 1D ) and invasive ability (Fig. 1E) . However, the Bax∆2-positive clone #10 had significantly less capability in colony formation compared with the Bax∆2-negative clone #28 (Fig. 1F) . These results indicate that Bax∆2-positive cells may be less tumorigenic in tumor development.
Bax∆2-positive subline cells are sensitive to a subgroup of chemotherapeutics
We have previously shown that cancer cells with Bax microsatellite mutations, such as prostate cancer 104-R cells (G7/G7) and colon cancer LoVo cells (G7/G9), are more sensitive to Adriamycin treatment than cancer cells with wild type Bax (36) . However, the heterogeneity of different cell lines often adds complexity to data interpretation. To address this issue, we compared HCT116 isogenic subline clone #10 (Bax∆2-positive) and clone #28 (Bax2-negative) cells for their sensitivities to chemotherapeutic agents. For the initial screening, we selected a panel of different classes of commonly used chemotherapeutic drugs. Cells were treated with a series of doses of each drug, and the results of cell death are shown in Table 2 . Bax∆2-positive clone #10 was more sensitive to Adriamycin than Bax2-negative clone #28, which was consistent with the previous report that Bax∆2-positive cancer cells are more sensitive to Adriamycin than Bax∆2-negative cancer cells (36) . In addition, Bax∆2-positive clone #10 was also highly sensitive to 5-FU, a pyrimidine analogue compared with the Bax2-negative clone #28 (Table 2) . Interestingly, the sensitivity seems selective, even within the same class of chemotherapeutic drugs because there was no significant difference when both clones were treated with Daunorubicin, which is also an anthracycline antibiotic with a similar structure as Adriamycin (Table 2 ). These data indicate that Bax∆2-positive cells may have a therapeutic advantage or preference to a subgroup of chemotherapeutic drugs.
Bax∆2 promotes apoptosis through activation of the caspase-8 pathway
Bax typically targets the mitochondria upon activation and results in the activation of the caspase-9 and caspase-3 cascade for cell death (40) . To determine the underlying mechanism by which Bax∆2 promoted cell death, HCT116 clones #10 and #28 were treated with Adriamycin or 5-FU in the presence of different caspase inhibitors. We found that the chemodrug-induced apoptosis was significantly augmented in clone #10 and could be effectively inhibited by either a caspase-8 or caspase-3 inhibitor, but not caspase-1 or caspase-9 inhibitor (Fig. 2A) . The caspase-3 activity was confirmed by the caspase-3 fluorometric assay (Fig. 2B) . The activation of caspase-3 was not surprising, because it is an executioner caspase downstream of many caspasemediated cell death events, including the Bax mitochondrial death pathway (24, 25) . However, the activation of caspase-8 was unexpected, as the Bax family usually utilizes the mitochondrial death pathway (24, 25) . Consistent with this notion, immunoblotting analysis using an anti-active caspase-8 antibody revealed that caspase-8 was activated, as indicated by the appearance of the cleaved caspase-8 fragments (43 kDa and 18 kDa), in clone #10 when treated with Adriamycin or 5-FU but not in clone #28 (Fig. 2C) . Thus, Bax∆2 promoted apoptosis through the activation of caspase-8 and its downstream executioner caspase-3.
Activation of the Bid mitochondrial pathway is not essential for the onset of Bax∆2-induced apoptosis
Caspase-8 is one of the initiator caspases in the extrinsic death receptor pathway (41) . Once activated, caspase-8 directly activates the executioner caspase-3, or cleaves the BH-3-only protein Bid into tBid, which in turn targets mitochondria and triggers the release of cytochrome c for apoptosis (42, 43) . We next determined if the Bid-dependent mitochondrial death pathway was required for Bax∆2 to promote apoptosis. We found that Bid was partially degraded in the Bax∆2-positive clone #10 cells treated with 5-FU or Adriamycin but not in the Bax∆2-negative clone #28 cells (Fig. 3A) . However, inhibition of Bid activity by its specific siRNA or inhibitor did not significantly affect the chemodrug-induced apoptosis (Fig. 3B) 
obtained using a caspase-9 inhibitor or ectopic expression of the caspase-9 dominant negative mutant (44) (Fig. 3C) . Furthermore, caspase-8 was activated as early as 8 h and reached to its maximum activity by 16 h, but the mitochondria membrane potential remained reasonable intact 24 h post-treatment, as evidenced by simultaneously monitoring the caspase activity and mitochondrial membrane potential (Figs. 3D and E) . Taken together, these data indicate that the Bid-dependent mitochondrial death pathway may not be essential for the onset of chemodruginduced apoptosis in the Bax∆2-positive cells. Direct activation of caspase-3 by caspase-8 is likely required for the onset of the apoptosis.
Bax∆2 activates caspase-8 by recruiting it into proximity
Caspase-8 is usually activated by death receptor-mediated self-processing, i.e., the proximityinduced dimerization, followed by aggregation and self-cleavage/activation (45) . We speculated whether Bax∆2 oligomers or aggregates might serve as a platform to recruit caspase-8 into the proximity for activation. To test this hypothesis, we first examined whether Bax∆2 and caspase-8 were localized together. Bax null mouse embryonic fibroblast (MEFs) were transfected with Bax∆2 and the activation of caspase-8 was confirmed by immunoblotting analysis with an anticleaved caspase-8 antibody (Fig. 4A) . Immunostaining showed that in the absence of Bax∆2, the staining of caspase-8 was weak and appeared as diffused fine granules (Fig. 4B, top panel) .
Upon the expression of Bax∆2, caspase-8 became aggregated and co-localized with Bax∆2 ( anti-Bax∆2 antibody than that with the IgG control (Fig. 4C) . These data suggest that Bax∆2 oligomers may serve as a platform for caspase-8 aggregation and activation.
Discussion
Bax is a pro-apoptotic tumor suppressor and is expressed in almost all types of human cells (21, 46) . Exon 3 of Bax contains a microsatellite sequence that is prone to mutation due to replication slippage if the mismatch repair system is impaired (47, 48) . A single guanine nucleotide deletion from G8 to G7 is the most common mutation in colorectal cancer with microsatellite instability, thus resulting in an apparent Bax null phenotype (47, 48) . Interestingly, alternative splicing of Bax exon 2 can rescue the frameshift mutation, generating a unique and functional Bax∆2 isoform (36) . In this report, we demonstrated that cancer cells harboring Bax G7/G7 alleles were capable of producing Bax∆2 transcripts and proteins, although the levels of Bax2 transcripts and proteins were extremely low and unstable (Figs. 1B and C) . Bax∆2-positive cells were selectively sensitive to a subgroup of chemotherapeutics, such as 5-FU and Adriamycin (Table 2 and Fig. 2) . Surprisingly, Bax∆2-promoted-apoptosis relied on the activation of caspase-8 and downstream caspase-3 (Fig. 2) . The Bid-mitochondrial pathway appeared not essential for onset of the apoptosis (Fig. 3) . The mechanism underlying caspase-8 activation by Bax2 was most likely through physical interactions between Bax∆2 and caspase-8 resulting in the formation of aggregates thereby triggering the apoptotic process (Fig. 4) .
There are two criteria in the generation of BaxΔ2. First, the Bax gene must have the deletion of a single guanine nucleotide (G8 to G7) in its exon 3 microsatellite tract. Second, the alternative splicing machinery needs to be able to remove most of exon 2 (36) . Previously, we have shown gene assay (37) . Thus, any Bax G7 allele, theoretically, is able to generate Bax∆2. However, our current results showed that Bax∆2 transcripts and proteins were only detected in cells harboring the Bax G7/G7 alleles (Fig. 1B) . Furthermore, only less than 20% of total pre-mRNA from the Bax G7/G7 population went through exon 2 alternative splicing (Fig. 1B) . Neither alternative splicing nor the Bax∆2 protein was detected in all Bax G8/G7 subclones tested (Table 1) .
However, the underlying mechanism is not known. One possibility is that the amount of Bax∆2 generated by Bax G8/G7 is too low to be detected. Another possibility is that there is a potential inhibitory mechanism for alternative splicing to occur in Bax G8/G7 cancer cells. Future studies are needed to test these possibilities.
Bax usually promotes apoptosis through activation of the intrinsic mitochondria death pathway (49, 50) . Unlike Bax and other known Bax isoforms, Bax2 lacks exon 2, which is critical for the mitochondria targeting (33) . Although ectopically expressed Bax∆2 is able to activate the mitochondrial death pathway, it does not mean that Bax∆2 directly targets mitochondria (36).
Our results indicate that caspase-8 via caspase-3 is essential for the onset of Bax∆2-induced apoptosis, and that mitochondria may act as an amplifier for the death process. Future studies are needed to explore whether this unique pro-apoptotic feature of Bax2 is related to its ability to sensitize some "Bax-negative" MSI tumor cells to a subgroup of chemotherapeutic drugs. 
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